These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 2512355)

  • 1. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
    Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
    J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
    de Fries RU; Golub SH
    J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential modulation of LAK and ADCC functions of natural killer cells from AK-5 tumor-bearing rats by IL-2, IL-12 and IFN-gamma.
    Muralikrishna K; Varalakshmi C; Khar A
    Cytokines Cell Mol Ther; 1997 Mar; 3(1):51-8. PubMed ID: 9287244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of various cytokines on the induction of lymphokine-activated killer cells.
    Bergmann L; Weidmann E; Bungert B; Hechler P; Mitrou PS
    Nat Immun Cell Growth Regul; 1990; 9(4):265-73. PubMed ID: 2120581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
    Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
    J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
    Blanchard DK; Djeu JY
    J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
    Reiter Z; Taylor MW
    Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
    J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
    Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
    J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor targets stimulate IL-2 activated killer cells to produce interferon-gamma and tumor necrosis factor.
    Chong AS; Scuderi P; Grimes WJ; Hersh EM
    J Immunol; 1989 Mar; 142(6):2133-9. PubMed ID: 2493506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells.
    Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY
    J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity.
    Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M
    Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mannoprotein-induced anti-U937 cell cytotoxicity in peripheral blood mononuclear cells from uninfected or HIV-infected subjects: role of interferon-gamma and tumor necrosis factor-alpha.
    Gomez MJ; Torosantucci A; Quinti I; Testa U; Peschle C; Cassone A
    Cell Immunol; 1993 Dec; 152(2):530-43. PubMed ID: 8258154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial characterization of a lymphokine pathway for the immunologic induction of tumor necrosis factor-alpha release from human peripheral blood mononuclear cells.
    Kornbluth RS; Gregory SA; Edgington TS
    J Immunol; 1988 Sep; 141(6):2006-15. PubMed ID: 3139748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones.
    van de Griend RJ; Ronteltap CP; Gravekamp C; Monnikendam D; Bolhuis RL
    J Immunol; 1986 Mar; 136(5):1700-7. PubMed ID: 3005399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
    Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
    Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-4 differentially regulates interleukin-2-mediated and CD2-mediated induction of human lymphokine-activated killer effectors.
    Robinet E; Kamoun M; Farace F; Chouaib S
    Eur J Immunol; 1992 Nov; 22(11):2861-5. PubMed ID: 1358624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.